Skip to content
GLP-1 Desk
Menu
Dispatch #447

MEDVidi

MEDVidi is a US telehealth platform whose licensed providers evaluate patients and prescribe GLP-1 weight-management medications, including brand-name Zepbound (tirzepatide) and Wegovy (semaglutide), plus…

Visit MEDVidiAssume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way.
Semaglutide
Not disclosed
Tirzepatide
Not disclosed
Coverage
Coverage not published
Brand-name
Yes

Line MEDVidi up against its closest alternatives. Or go one-on-one: MEDVidi vs CoreAge Rx.

Desk Score breakdown

Each of the six scored dimensions. See the methodology.

Price transparency30/100
State access24/100
Molecule range53/100
Onboarding speed66/100
Support responsiveness70/100
Licensing & trust68/100

What the Desk likes

  • Licensed providers can prescribe brand-name Zepbound and Wegovy
  • Transparent flat consultation fees (195 dollar initial, 159 dollar follow-up)
  • Prescriptions sent to the patient's pharmacy of choice, so insurance can be used

Where points come off

  • Consult-fee model: medication is not included and its cost is separate
  • No medication pricing is published
  • State list is shown as a map rather than enumerated

The Desk's briefing — C

Best for: People who want a licensed provider to prescribe brand glp-1 they fill with insurance.

MEDVidi ranks #447 of 498 providers scored — see #1, CoreAge Rx on the board.

Related dispatches

Everyone else on the board (18)

Pricing and verification reflect MEDVidi's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on MEDVidi's site. Not medical advice; see our disclosure.

← Back to The Desk